VCID: 17604343
    Profile

    Corporate information

    Official name
    Hylomorph AG
    Investment activity status
    Active investor


    Overview

    Tens of millions of people live today with one or more surgical implant. Every time a patient receives a surgical implant, the immune system initiates a foreign body reaction. The implant becomes covered by a thick layer of fibrotic tissue, which hardens and contracts over time in an attempt of isolating, killing and expelling the foreign body. Hylomorph aims at minimizing post-surgical complications in medical implants, thus improving patients' quality-of-life and reducing associated healthcare costs. Hylomorph provides clinicians with ready-to-use conformal covers for implantable medical devices. A proprietary technology minimizes the incidence of post-operative complications such as infection, by preventing the onset of fibrotic tissue encapsulation and microbial contamination.

    Funding rounds

    Change in valuation: unknown

    Profile Country Notes
    Verve Capital Partners AG Switzerland Initial investment. Round participant.

    Change in valuation: unknown

    Profile Country Notes
    Fongit Seed Invest Initial investment. Round participant.

    Change in valuation: unknown

    Profile Country Notes
    Lichtsteiner Stiftung Initial investment. Round participant.

    Change in valuation: unknown

    Profile Country Notes
    Zurich Cantonal Bank Switzerland Initial investment. Round participant.